Avadel Pharmaceuticals plc announced the publication of survey data describing clinician preferences among oxybate treatments for patients living with narcolepsy. Discrete choice experiments (DCE) are studies designed to characterize and quantify drivers of preferences for attributes. Clinicians selected from hypothetical, randomly generated medicine profiles to determine which medication they preferred overall, which would improve patient quality of life, and which would reduce patient anxiety and stress.

Similarly, frequency of oxybate treatment dosing, driven by once-nightly dosing, was more than double in relative importance, for patient quality of life and for reducing patient anxiety/stress, than other attributes. This DCE validates a previously published DCE in patients, in which dosing frequency was also shown to be the most important driver of patients' preferred oxybate treatment. These data underscore the long unmet need for an oxybate treatment that does not require middle-of-the-night dosing.